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Purpose: To investigate safety, tolerability, and
pharmacokinetic properties of single and multiple
doses of novel translocator protein 18 kDa antagonist
ONO-2952 in healthy subjects.
Methods: Double-blind, placebo-controlled single
(SAD) and multiple (MAD) dose escalation studies
were conducted. Healthy men and women aged 18 to
55 years inclusive and without history of psychiatric
disorders were eligible. Forty-eight volunteers received
single doses of ONO-2952 (3, 10, 30, 100, 200, or
400 mg) or placebo under fasted conditions (SAD
study), and 36 received ONO-2952 (30, 60, or 100
mg/d) or placebo for 21 consecutive days under fed
conditions (MAD study). ONO-2952 10 and 200 mg
were administered under fasted and fed conditions in
the SAD study to investigate the effect of food on the
absorption of ONO-2952. Safety assessments in-
cluded adverse events, vital signs, 12-lead ECGs, and
clinical laboratory evaluations. Plasma and urine
pharmacokinetic proﬁles of ONO-2952 were deter-
mined.
Findings: Across both studies, mean age ranged
from 29.8 to 39.8 years, most participants were white,
and the proportion of female volunteers was 52%. No
treatment or dose-related trends in adverse events
were observed. The most frequent adverse events were
headache and presyncope (n ¼ 2 each [SAD study])
and constipation and headache (n ¼ 3 each [MAD
study]). All headache and constipation episodes were
possibly related to the study drug. Plasma ONO-2952
concentrations peaked 2.5 to 3.5 hours (SAD study)
and 3.0 to 4.0 hours (MAD study) postdose. ONO-
2952 systemic exposure increased less than dose
proportionally under fasted conditions. Fed conditionsSeptember 2015signiﬁcantly increased exposure compared with fasted
conditions: geometric mean ratios of Cmax (90% CIs)
were 229% (176–299 [10 mg]) and 778% (623–971
[200 mg]), and AUClast were 159% (131–192 [10
mg]) and 382% (288–506 [200 mg]). In the MAD
study, the systemic exposure of ONO-2952 increased
in a slightly greater than dose-proportional manner.
Geometric mean accumulation ratios (95% CI) of
AUC24 were 2.50 (2.09–2.98 [30 mg]), 2.23 (1.85–
2.68 [60 mg]), and 2.73 (2.10–3.55 [100 mg]); and
Cmax were 1.65 (1.43–1.90 [30 mg]), 1.56 (1.31–1.85
[60 mg]), and 1.85 (1.38–2.49 [100 mg]).
Implications: ONO-2952 was safe and well toler-
ated in these early clinical studies investigating safety,
tolerability, and pharmacokinetic properties of single
and multiple doses. ONO-2952 systemic exposure
increased in a less than dose-proportional manner
under fasted conditions and in a slightly greater than
dose-proportional manner under fed conditions. These
results support the progression of ONO-2952 to
further studies in humans. SAD study: ClinicalTials.
gov identiﬁer: NCT01364441. MAD study: Clinical-
Trials.gov identiﬁer: NCT01489345. (Clin Ther.
2015;37:2071–2084) & 2015 The Authors. Published
by Elsevier HS Journals, Inc.
Key words: ONO-2952, healthy subjects, pharma-
cokinetics, safety, translocator protein 18 kDa.2071
Clinical TherapeuticsINTRODUCTION
The translocator protein 18 kDa (TSPO), previously
known as the peripheral benzodiazepine receptor and
the mitochondrial benzodiazepine receptor, is a 5
transmembrane domain protein located on the outer
mitochondrial membrane. It is expressed ubiqui-
tously in peripheral tissues and in the glial and
ependymal cells of the central nervous system.1–3
TSPO binds several ligands, both synthetic and
endogenous, with high afﬁnity.4,5 It is the binding
of TSPO to cholesterol (the metabolic precursor
for steroid biosynthesis) that underpins its role in
steroid production, during which TSPO trans-
ports cholesterol from intracellular stores into the
mitochondria.5,6
The expression of TSPO within glial cells of the
brain, such as astrocytes, microglia, and oligoden-
drocytes,7,8 suggests it may be associated with patho-
logic manifestations. Neurologic lesions, such as
those caused by brain damage, neuroinﬂammation,
or psychiatric disorders, can be characterized by
upregulation of these cells. As such, increased levels
of TSPO are often detected in psychologic or neuro-
logic disorders and imaging of TSPO via radioligands
has been developed as a diagnostic tool.3 In peripheral
tissues, increased expression levels of TSPO are
observed in cells associated with various cancerous
tumor types, inﬂammation, and cardiovascular
disease.9
Neurosteroidogenesis, the production of steroids
within the nervous system, is a mechanism by which
TSPO may have a functional role in disease processes.
Neurosteroids alter the balance of excitatory and
inhibitory neurotransmission by modulating neuronal
excitability via ion channels and other cell surface
receptors.10,11 The transport of cholesterol across the
mitochondrial membrane is rate-limiting in this proc-
ess; thus, TSPO activity can regulate neurosteroid
production and the binding of TSPO ligands has been
shown to stimulate neurosteroidogenesis.2,12 There-
fore, modifying the activity of TSPO may have
implications for pharmacologic intervention in many
diseases.
ONO-2952 is a novel and selective TSPO antago-
nist that binds with high afﬁnity to TSPO in mito-
chondrial tissue preparations in vitro.13 Antagonism
of TSPO by ONO-2952 has been shown to inhibit
restraint stress-induced production of the neurosteroid
precursor pregnenolone in the hippocampus and2072noradrenaline release in the amygdala in rats, and
thus has the possibility of normalizing the balance of
excitatory and inhibitory neurotransmission.13 Further-
more, ONO-2952 has been shown to attenuate bowel
dysfunction in a rat restraint stress model as well as
stress-induced defecation and freezing behavior in a rat
conditioned fear stress model.13 The antagonistic mode
of action of ONO-2952 at TSPO provides a potentially
novel pharmacologic intervention that may have ther-
apeutic potential in many conditions due to over-
expression of TSPO in many disease states.14
The present Phase I studies were designed to
investigate the safety, tolerability, and pharmacoki-
netic properties of ONO-2952 in healthy volunteers
following the administration of single and multiple
daily doses.METHODS
Subjects
Male and female subjects aged 18 to 55 years
inclusive, with a body mass index of 19 to 35
inclusive, were eligible for inclusion. All subjects were
considered healthy, as determined by medical history,
physical examination, vital signs, 12-lead ECG, and
clinical laboratory tests. All subjects provided written
informed consent.
Women were surgically sterile, postmenopausal, or
if of child-bearing potential they agreed to use double-
barrier method contraception for the duration of study.
Key exclusion criteria included a history or pres-
ence of any clinically signiﬁcant psychiatric disease or
disorder, a history or presence of any cardiovascular
or gastrointestinal disorder, and any clinically signiﬁ-
cant drug or food allergy. Subjects were also excluded
if they had used nicotine or any investigational
medication within 6 months, prescription drugs
within 14 days, nonprescription drugs within 7 days,
or consumed alcohol or caffeine within 48 hours
before dosing.
Study Design
These were single-center, Phase I, randomized,
double-blind, placebo-controlled, single ascending
dose (SAD) and multiple ascending dose (MAD)
studies.
Both studies were conducted in accordance with US
federal regulations, Good Clinical Practice, and the
ethical principles that have their origins in theVolume 37 Number 9
F. Suto et al.Declaration of Helsinki. The protocols were submitted
for ethical review and approval was obtained in
writing from the investigational site’s institutional
review board (IntegReview Ethical Review Board,
Austin, Texas).
SAD Study
The SAD study consisted of 3 periods: screening
(Day –22 to –2), dosing and evaluation (Day –1 to 4)
during which patients were admitted to the investiga-
tional site, and follow-up for a maximum of 1 week
after dosing (Day 5–8). Forty-eight subjects were
enrolled in 6 cohorts of 8 subjects, randomized in a
3:1 ratio (ONO-2952:placebo). A single dose of
ONO-2952 (3, 10, 30, 100, 200, and 400 mg) or
placebo was administered following an overnight fast.
In food effect cohorts, (10 and 200 mg), subjects
underwent an 11-day washout period before receiving
an additional dose of ONO-2952 under fed condi-
tions (dosing took place 30 minutes after the start of a
high-fat, high-calorie breakfast consistent with US
Food and Drug Administration guidelines in that
approximately 50% of total energy content of the
meal was derived from fat). Blood and urine samples
were collected to characterize the pharmacokinetic
proﬁle of ONO-2952. Blood samples were collected
predose and 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48,
and 72 hours postdose in all subjects. Blood samples
were processed to plasma and were stored at –701C or
below. Urine samples from subjects receiving ONO-
2952 3 and 400 mg were collected predose and at the
following intervals postdose: 0 to 12, 12 to 24, 24 to
36, 36 to 48, 48 to 60, and 60 to 72 hours. Urine
samples were stored at –701C or below.
MAD Study
The MAD study consisted of 3 periods: screening
(Day –22 to –2), dosing, and evaluation (Day –1 to
24) during which patients were admitted to the
investigational site, and follow-up for a maximum
of 2 weeks after the last dose (Day 25–36). Thirty-six
subjects were enrolled in 3 cohorts of 12 subjects,
randomized in a 3:1 ratio (ONO-2952:placebo).
ONO-2952 30, 60, or 100 mg or placebo was
administered once daily for 21 days under fed
conditions (dosing took place 30 minutes after
the start of a standard breakfast based on the
Step 2 American Heart Association Diet offering
daily nutrition of approximately 30% fat, 55%September 2015carbohydrate, and 15% protein). Blood samples
were collected predose on Days 1, 2, 4, 7, 10, 12,
14, 16, 18, and 21; and 0.25, 0.5, 1, 2, 3, 4, 6, 8, and
12 hours postdose on Days 1 and 21, with additional
samples taken at 24, 36, 48, and 72 hours postdose on
Day 21. Blood samples were processed to plasma and
stored at –701C or below.
Safety Analysis
For both studies, adverse events were monitored
and recorded from the time of administration of
the study drug until the end of study and coded
using MedDRA (Medical Dictionary for Regulatory
Activities) (MSSO, U.S.A) version 14.1. Subjects
underwent assessment of clinical laboratory evalua-
tions, 12-lead ECG and vital signs, including blood
pressure, pulse rate, respiratory rate, and body tem-
perature at regular intervals throughout both studies.
Psychiatric effects were assessed in the MAD study
using the Personal Health Questionnaire Depression
Scale, Generalized Anxiety Disorder 7-Item Scale, and
Columbia–Suicide Severity Rating Scale.
Bioanalysis
SAD Study
Plasma and urine ONO-2952 concentrations were
determined using a validated HPLC-MS method with
quantitative range of 5 pg/mL to 10 ng/mL and 1 to
1000 ng/mL, respectively. Plasma samples were
diluted using a range of dilution factors up to 1000-
fold to allow quantiﬁcation in the range of 5 pg/mL to
10 ng/mL. In addition, dilution reproducibility at
1000-fold was conﬁrmed as part of the assay valida-
tion. An internal standard, deuterated form of ONO-
2952 was added to all plasma samples; analytes were
isolated through solid-phase extraction and eluted
with formic acid/methanol (1:50, v/v) using Oasis
HLB (60 mg/3 cc) and Oasis MCX (Waters, USA)
(60 mg/3 cc) cartridges. The eluate was evaporated
under a nitrogen stream and the remaining residue
was reconstituted with 5 mmol/L ammonium formate/
acetonitrile (1:1, v/v) and injected into an HPLC-MS
(AB Sciex (SCIEX, USA) API 5000). An Inertsil ODS-
4 (GL Sciences, Japan) column (2.1 mm internal
diameter (I.D.)  100 mm; particle size, 2 μm) was
used as the analytical column, and 5 mmol/L ammo-
nium formate and acetonitrile were used as the mobile
phases. The positive ion detection mode was used,
and the concentrations of ONO-2952 and the internal2073
Clinical Therapeuticsstandard were determined by the multiple reaction
monitoring method (ONO-2952, m/z 399- m/z 340;
internal standard, m/z 404 - m/z 343). Incurred
sample reanalysis was performed to verify the
reliability of obtained plasma concentrations and
the results of incurred sample reanalysis showed
that the assay variability was within 20% in all
reanalyzed samples, which met the quality control
standards.
A urine sample was added with acetonitrile
and internal standard, and diluted with 5 mmol/L
ammonium formate/acetonitrile (1:1, v/v). The result-
ing sample was injected into a high-performance
LC-MS. A Unison UK-C18 (Imtakt, USA) column
(2 mm I.D.  50 mm; particle size, 3 μm) was used
as the analytical column, and 5 mmol/L ammonium
formate and acetonitrile were used as the mobile
phases. The positive ion detection mode was used,
and the concentrations of ONO-2952 and the internal
standard were determined by the same multiple reac-
tion monitoring method used for the plasma samples.MAD Study
Plasma ONO-2952 concentrations were determined
using a cross-validated LC-MS method with quantitative
range of 0.5 to 1000 ng/mL. The quantitative range was
reﬁned following information about human exposure to
ONO-2952 from the SAD study. Plasma samples were
added with internal standard; analytes were isolated
through solid-phase extraction using Oasis HLB (10 mg/
96 well) and eluted with acetonitrile. The eluate was
evaporated under a nitrogen stream. The remaining
residue was reconstituted with 5 mmol/L ammonium
formate/acetonitrile (4:6, v/v) and injected into the LC-
MS system. The subsequent analytical procedures were
as described for the single ascending dose study. A
Cadenza CD-C18 (Imtakt, USA) column (2 mm I.D. 
100 mm; particle size, 3 μm) was used as the analytical
column, and 5 mmol/L ammonium formate / acetonitrile
(4:6, v/v) was used as the mobile phases. The positive
ion detection mode was used, and the concentrations of
ONO-2952 and the internal standard were determined
by the same multiple reaction monitoring method used
for the samples collected in the SAD study.Pharmacokinetic Profile
The pharmacokinetic parameters of ONO-2952
were calculated by a noncompartmental model using2074Phoenix WinNonlin version 6.1 (Certara, St Louis,
Missouri).
SAD Study
Cmax, Tmax, and AUClast were calculated from
plasma concentrations of ONO-2952. At all doses,
the AUClast represented less than 80% of AUC1
in most subjects. Hence, parameters dependent on
estimation of the terminal elimination rate constant
(lambda z) such as t½, CL/F, and Vd/F were not
reported.
MAD Study
Cmax, Tmax, AUC0–24), and t½ were calculated from
plasma concentrations of ONO-2952. The accumu-
lation ratios of AUC24 between Day 1 and Day 21
were also calculated.
Statistical Analysis
Statistical analyses were performed using Statistical
Analysis Software version 9.1.3 or 9.2 (SAS Institute
Inc, Cary, North Carolina). Study populations ana-
lyzed were the Safety Set, all enrolled subjects who
received study medication, and the Pharmacokinetic
Evaluable Set, all enrolled subjects who received
ONO-2952 and provided sufﬁcient samples for phar-
macokinetic evaluations. All safety data and pharma-
cokinetic parameters were summarized by treatment
group using descriptive statistics. Statistical testing
was performed 2-sided at the α¼ 0.05 level.
SAD Study
Dose proportionality of Cmax and AUClast was
evaluated using the power model.14 The point
estimate of the intercept (ln[α]) and slope (β) with
90% CI was calculated by linear regression according
to the least squares method. Food effect on Cmax,
AUClast, and Tmax was evaluated at ONO-2952 10
and 200 mg. Natural-log transformed Cmax and
AUClast were analyzed using a mixed ANOVA model.
The geometric mean ratios and 90% CIs were deter-
mined. For Tmax, a 2-tailed Wilcoxon signed-rank test
was used and the resulting P value presented.
MAD Study
Dose proportionality of Cmax and AUC24 was
evaluated after Day 21 using the same power model.
The point estimate of the intercept and slope with
90% CIs were calculated by linear regression,Volume 37 Number 9
F. Suto et al.as described above. The accumulation ratios were
calculated as RAUC24 (AUC24hDay 21/AUC24hDay 1)
and RCmax (CmaxDay21/CmaxDay1) (R is the accumula-
tion factor; ratio of drug concentration observed
during the dosing interval at steady-state (here this is
Day 21) divided by drug concentration seen during
the dosing interval after a single (ﬁrst) dose (here this
is Day 1)). The geometric mean and 95% CI of these
ratios were calculated as follows: the mean of natural
log-transformed values of the ratios and their 95% CI
were calculated and the values obtained were expo-
nentially back-transformed to the original scale. The
accumulation ratios of subjects whose pharmacoki-
netic parameters on the ﬁrst or last dosing day were
judged not to be appropriately evaluated were not
used for the calculation of the geometric mean ratios
and 95% CI.Screening
(n=311)
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(n=48)
Cohort 2
Fasted
Placebo (n=2)
ONO-2952
10 mg (n=6)
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Figure 1. Patient consort flow diagram for single ascend
September 2015RESULTS
Subject Disposition and Demographic
Characteristics
SAD Study
A total of 48 subjects were enrolled: 36 subjects
received ONO-2952 and 12 subjects received placebo.
All subjects completed the study (Figure 1).
MAD Study
Thirty-six subjects were enrolled: 27 subjects
received ONO-2952 and 9 received placebo. Three
subjects did not complete the study: 2 subjects were
discontinued from the study at the investigator’s
discretion because of adverse events (ONO-2952 30
mg: ventricular tachycardia; ONO-2952 100 mg: mus-
culoskeletal chest pain and asthenia), the third subject
(ONO-2952 60 mg) was lost to follow-up (Figure 2).Screening failure, withdrew consent,
did not complete screening, eligible
but not used (n=263)
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Figure 2. Patient consort flow diagram for multiple ascending dose study.
Clinical TherapeuticsDemographic characteristics of subjects for both
studies are presented in Table I.
Safety
SAD Study
The overall incidence of adverse events experienced
was low and ranged from 0% to 33% of subjects after
a single dose of ONO-2952: 7 subjects experienced 11
adverse events (Table II). Two subjects experienced
headache and 2 subjects presyncope. All other adverse
events were reported by 1 subject each. Adverse events
judged possibly related to study drug were head-
ache (n ¼ 2), diarrhea (n ¼ 1), and involuntary
muscle contractions (n ¼ 1). All adverse events
were mild, with the exception of 1 episode of
presyncope, which was classed as moderate and
considered unrelated to ONO-2952. All adverse events
resolved without intervention. No treatment, dose, or
food-related trends were observed in the incidence of
adverse events, clinical laboratory results, vital sign
measurements, or 12-lead ECG readings.2076MAD Study
Twelve subjects experienced 27 adverse events (pla-
cebo, n ¼ 2; ONO-2952 30 mg, n ¼ 3; 60 mg, n ¼ 4;
and 100 mg, n ¼ 3) (Table III). Constipation and
headache were the most frequent adverse events,
experienced by 3 subjects each. Nineteen adverse events
were judged possibly related to study drug, including
constipation, diarrhea, nausea, salivary hypersecretion,
dizziness, headache, abnormal dream, sleep disorder, and
cold sweat. Two subjects were withdrawn from the study
at the Investigator’s discretion because of adverse events
(ONO-2952 30 mg: ventricular tachycardia; ONO-
2952 100 mg: musculoskeletal chest pain and asthenia),
although these adverse events were judged to be unrelated
to the study drug.
All adverse events resolved without intervention,
with the exception of 1 subject who experienced mild
constipation in the ONO-2952 60 mg cohort who was
lost to follow-up and so the ﬁnal status of the adverse
event remains unknown. No treatment or food-related
trends were observed in the incidence of adverseVolume 37 Number 9
Table I. Summary of patient demographic characteristics (Safety Set).
SAD MAD
Placebo ONO-2952 Placebo ONO-2952
Parameter (n ¼ 12)
3 mg
(n ¼ 6)
10 mg
(n ¼ 6)
30 mg
(n ¼ 6)
100 mg
(n ¼ 6)
200 mg
(n ¼ 6)
400 mg
(n ¼ 6) (n ¼ 9)
30 mg
(n ¼ 9)
60 mg
(n ¼ 9)
100 mg
(n ¼ 9)
Age, y* 33.5 (12.9) 30.0 (12.0) 39.8 (11.9) 30.0 (9.8) 30.0 (12.3) 31.2 (6.3) 29.8 (10.2) 34.4 (7.6) 34.0 (7.1) 33.2 (11.1) 34.4 (9.1)
Sex†
Female 6 (50) 3 (50) 3 (50) 3 (50) 4 (67) 4 (67) 3 (50) 5 (56) 4 (44) 5 (56) 4 (44)
Race†
White 8 (67) 5 (83) 3 (50) 5 (83) 6 (100) 5 (83) 3 (50) 6 (67) 4 (44) 7 (78) 8 (89)
Black or African
American
4 (33) 1 (17) 3 (50) 1 (17) 0 (0) 1 (17) 3 (50) 3 (33) 4 (44) 2 (22) 1 (11)
Height, cm* 166.4 (8.0) 173.0 (10.5) 169.8 (9.5) 169.3 (7.1) 165.5 (10.1) 167.3 (4.3) 169.0 (13.7) 166.6 (5.5) 171.1 (11.8) 171.6 (10.3) 165.7 (10.6)
Weight, kg* 78.3 (9.5) 74.4 (21.9) 79.5 (20.0) 80.6 (12.2) 76.5 (10.8) 65.5 (9.2) 85.3 (24.4) 80.7 (11.8) 77.9 (16.8) 73.6 (17.5) 73.1 (16.8)
Body mass index* 28.2 (3.9) 24.3 (4.2) 27.3 (5.5) 28.0 (3.1) 27.9 (4.9) 23.3 (2.6) 29.3 (5.2) 29.0 (3.4) 26.5 (4.2) 24.7 (3.4) 26.4 (3.7)
SAD ¼ single ascending dose trial; MAD ¼ multiple ascending dose trial.
*Values are presented as mean (SD).
†Values are presented as n (%).
Table II. Adverse events (AEs) reported by healthy volunteer subjects after a single dose of ONO-2952 (Safety Set).
ONO-2952
Placebo 3 mg 10 mg 30 mg 100 mg 200 mg 400 mg
Fasted Fed Fasted Fasted Fed Fasted Fasted Fasted Fed Fasted
AE (n ¼ 12) (n ¼ 4) (n ¼ 6) (n ¼ 6) (n ¼ 6) (n ¼ 6) (n ¼ 6) (n ¼ 6) (n ¼ 6) (n ¼ 6)
No. of AEs/No. of subjects 0/0 0/0 1/1 3/2 1/1 2/1 0/0 1/1 3/2 0/0
Subjects with Z1 AE, % 0 0 17 33 17 17 0 17 33 0
AE (Preferred Term), n (%)
Headache 0 0 0 0 0 1 (17) 1 (17)* 1 (17)* 0
Presyncope 0 0 0 0 1 (17) 0 0 0 1 (17) 0
Abdominal pain 0 0 1 (17) 0 0 0 0 0 0 0
Diarrhea 0 0 0 1 (17) 0 0 0 0 0 0
Dermatitis contact 0 0 0 0 0 1 (17) 0 0 0 0
Muscle contractions involuntary 0 0 0 1 (17) 0 0 0 0 0 0
Musculoskeletal discomfort 0 0 0 1 (17) 0 0 0 0 0 0
*Subject experienced 41 occurrence of the same AE.
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Table III. Adverse events (AEs) reported by healthy volunteer subjects after multiple doses of ONO-2952
(Safety Set).
Placebo ONO-2952
(n ¼ 9) 30 mg (n ¼ 9) 60 mg (n ¼ 9) 100 mg (n ¼ 9)
No. of AEs/No. of subjects 2/2 12/3 9/4 4/3
Subjects with Z1 AE, % 22 33 44 33
AE (Preferred Term), n (%)
Constipation 0 2 (22) 1 (11) 0
Headache 1 (11) 1 (11) 1 (11) 0
Abnormal dreams 0 0 2 (22) 0
Nausea 0 1 (11) 1 (11) 0
Anxiety 0 1 (11) 0 0
Asthenia 0 0 0 1 (11)
Back pain 0 0 0 1 (11)
Cold sweat 0 0 1 (11) 0
Diarrhea 0 1 (11) 0 0
Dizziness 0 1 (11) 0 0
Flatulence 0 0 0 1 (11)
Musculoskeletal chest pain 0 0 0 1 (11)
Presyncope 0 0 1 (11) 0
Salivary hypersecretion 1 (11) 0 0 0
Sleep disorders 0 0 1 (11) 0
Urinary tract infection 0 0 1 (11) 0
Ventricular tachycardia 0 1 (11) 0 0
Clinical Therapeuticsevents, clinical laboratory results, vital sign measure-
ments, 12-lead ECG readings, or psychiatric assessments.
Pharmacokinetic Profile
SAD Study
After a single dose, ONO-2952 was absorbed and
reached Cmax between 2.5 and 3.5 hours postdose in
all cohorts under both fasted and fed conditions based
on median Tmax values, declining slowly over the 72-
hour sampling period (see Figure 3 and Table IV).
Predose concentrations of ONO-2952 were o5% of
Cmax in all subjects in the fed condition (ie, the second
treatment period); therefore, no adjustment was made
in the analysis between fasted and fed conditions.
Cmax increased in a less than dose-proportional
manner over the dose ranges analyzed with the point
estimates of β (3–400 mg: 0.68 [90% CI, 0.61–0.75],
3–200 mg: 0.74 [90% CI, 0.66–0.83], 3–100 mg:
0.76 [90% CI, 0.64–0.88], and 3–30 mg: 0.78 [90%
CI. 0.61–0.96]) (Figure 4). AUClast increased in a2078dose-proportional manner from 3 to 30 mg with the
point estimates of β (0.92 [90% CI, 0.83–1.00]), but
in a less than dose-proportional manner above 30 mg
(3–400 mg: 0.78 [90% CI, 0.73–0.84), 3–200 mg:
0.82 [90% CI, 0.76–0.89], and 3–100 mg: 0.83 [90%
CI, 0.75-0.91]) (Figure 4). Administration of ONO-
2952 in the fed condition resulted in a statistically
signiﬁcant increase in Cmax and AUClast compared
with fasted conditions (Figure 3). Statistical analysis of
the effect of dosing in the fed condition is presented in
Table V. For Cmax, the ratios of geometric means at
ONO-2952 10 mg and 200 mg were 229% (90% CI,
176–299) and 778% (90% CI, 623–971), respec-
tively. For AUClast, the ratios of geometric means at
ONO-2952 10 mg and 200 mg were 159% (90% CI,
131–192) and 382% (90% CI, 288–506), respec-
tively. The differences in Tmax between fed and fasted
conditions did not reach statistical signiﬁcance (P 4
0.05). Urine ONO-2952 concentrations were below
the limit of quantiﬁcation in all samples evaluatedVolume 37 Number 9
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Figure 3. Plasma concentration-time profiles of ONO-2952 after single oral administration to healthy
subjects (A) under the fasted or (B) under the fed and fasted conditions of the single ascending
dose study (mean [SD]) (n ¼ 6) (Pharmacokinetic Evaluable Set).
F. Suto et al.and no urine pharmacokinetic parameters were
calculated.
MAD Study
After multiple doses in the fed condition, median
maximum plasma concentrations of ONO-2952 were
observed at 3.0 to 4.0 hours postdose for all cohorts,
and mean t½ values were 37 to 42 hours (see Figure 5
and Table VI). The pharmacokinetic proﬁle of ONO-
2952 reached steady state for each dose by Day 10
based on trough concentrations (Figure 6). Cmax and
AUC24 values on Day 21 from 30 to 100 mg increased
in a slightly greater than dose-proportional manner
(see Figure 7 and Table VI). The point estimates of β
for Cmax and AUC24 over the range of ONO 2952 30
mg to 100 mg were 1.16 (90% CI, 0.98–1.35) and
1.20 (90% CI, 0.99–1.41), respectively. After once-
daily administration of ONO-2952 30, 60, and 100
mg for 21 days, geometric mean accumulation ratios
of AUC24 were 2.50 (95% CI, 2.09–2.98), 2.23 (95%
CI, 1.85–2.68), and 2.73 (95% CI, 2.10–3.55), re-
spectively, and those of Cmax were 1.65 (95% CI,
1.43–1.90), 1.56 (95% CI, 1.31–1.85), and 1.85
(95% CI, 1.38–2.49), respectively.DISCUSSION
These studies investigated the safety, tolerability, and
pharmacokinetic proﬁle of ONO-2952 in healthy
subjects following both single and multiple oral doses.
Results from these studies demonstrate that ONO-
2952 was well tolerated with no signiﬁcant safetySeptember 2015concerns after single doses up to 400 mg in fasted
conditions and up to 200 mg in fed conditions; and
during daily doses up to 100 mg over 21 days. No
serious adverse events were reported during the
studies, and no dose relationship was observed in
the incidence of adverse events or other safety assess-
ments.
In the SAD study, pharmacokinetic data indi-
cated that under fasted conditions increases in
exposure to ONO-2952 over the dose range tested
were generally less than dose proportional. Admin-
istration of ONO-2952 under fed conditions in-
creased the rate of absorption of ONO-2952 and
resulted in a statistically signiﬁcant increase in Cmax
and AUClast compared with fasted conditions. The
increased absorption of ONO-2952 in the fed state
supports administration with food in future clinical
trials. ONO-2952 demonstrated a relatively slow
rate of elimination following single dosing. This
resulted in the extrapolated portion of AUC1 being
420% in most subjects. Therefore, it was not
possible to calculate accurately the terminal elimi-
nation rate constant (lambda z) and several associ-
ated pharmacokinetic parameters (AUC1, CL/F, t½,
and Vd/F) could not be calculated reliably in this
study.
In the MAD study, pharmacokinetic data indi-
cated that under fed conditions exposure to ONO-
2952 increased with dose; however, both Cmax and
AUC24 values over the range of 30 to 100 mg
suggested a slightly greater than dose-proportional
increase in exposure to ONO-2952. Repeat dosing of2079
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Clinical Therapeutics
2080ONO-2952 indicated that the elimination rate of
ONO-2952 was independent of dose and the appa-
rent t½ of ONO-2952 ranged from 37 to 42 hours.
The accumulation ratios observed were comparable
across the doses tested (30, 60, and 100 mg) and
concentrations of ONO-2952 in the plasma reached
steady state by Day 10, as expected considering the
pharmacokinetic proﬁle following a single dose.
These safety and pharmacokinetic data combined
provide the basis for exploration of ONO-2952, a novel
and selective TSPO antagonist, in further clinical studies.
Modifying the activity of TSPO may have
implications for pharmacologic intervention in many
diseases. Increased TSPO expression is associated with
the inﬂammatory response, cellular repair, and cell
survival.15 Inhibition of TSPO activity can induceVolume 37 Number 9
Table V. Statistical analysis of food effect (fed or fasted).
ONO-2952
dose, mg Parameter
Ratio of
Least Squares
Geometric Means, %*
90% CI of
the Ratio, %†
10 AUClast (ng/h/mL) 159 131–192
Cmax (ng/mL) 229 176–299
200 AUClast (ng/h/mL) 382 288–506
Cmax (ng/mL) 778 623–971
*Natural-log transformed pharmacokinetic parameters (AUClast and Cmax) were analyzed using a mixed ANOVA model with
fasting status as a ﬁxed effect and subject as a random effect.
†Ratio (fed:fasted) and CIs were based on the exponentiated treatment differences.
F. Suto et al.apoptosis in various tumor cell types,16–18 whereas
high levels of TSPO expression are associated with
the most aggressive forms of cancer.19 However,
inhibition of TSPO can also restore myocardial
function in cardiovascular disorders and prevent
apoptosis in myocardial infarction.20–22 These studies
highlight that the role of TSPO in cell survival
is complex and targeting TSPO function may be
beneﬁcial in several pathologies.
Regulation of TSPO has demonstrated efﬁcacy in
several centrally mediated disease models. In rodents,
TSPO agonists can decrease neuron cell death and
reduce the inﬂammatory response following inducedDay1
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Figure 5. Plasma concentration-time profiles of ONO-
following multiple oral administration to health
8–9) (Pharmacokinetic Evaluable Set).
September 2015brain lesions,23,24 exert antidepressant and anxiolytic
effects in stress models,25,26 and promote analgesia in
inﬂammatory pain.27 Similarly, the novel TSPO
antagonist ONO-2952 reduces visceral hyperalgesia,
defecation, and freezing behavior in stress-induced
rats.13 These studies suggest that TSPO antagonism
may also be a plausible approach to regulate TSPO.
The ability of ONO-2952 to inhibit noradrenalin
release in the amygdala with a similar efﬁcacy to
diazepam in a rat restraint stress model13 supports the
notion that ONO-2952 may be efﬁcacious in a broad
range of stress-related disorders such as anxiety and
depression.10000
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Table VI. Pharmacokinetic parameters for ONO-2952 following multiple doses (Pharmacokinetic Evaluable Set).
Parameter*
Day 1 Day 21
ONO-2952
30 mg 60 mg 100 mg 30 mg 60 mg 100 mg
(n ¼ 9) (n ¼ 9) (n ¼ 9) (n ¼ 8) (n ¼ 9) (n ¼ 8)
Cmax (ng/mL) 197 (63.7) 388 (102) 752 (311) 344 (76.9) 605 (156) 1370 (259)
Tmax (h) 3.0 (2.0, 6.0) 3.0 (2.0, 4.0) 3.0 (2.0, 4.0) 3.0 (1.0, 4.0) 3.0 (2.0, 4.0) 4.0 (3.0, 6.0)
AUC24 (ng/h/mL) 1630 (380) 3270 (642) 6850 (2430) 4300 (926) 7500 (2300) 18,700 (3850)
t½ (h) — — — 42 (16) 37 (17) 42 (10)
*All data except for Tmax are expressed as mean (SD). Tmax is expressed as median (minimum, maximum).
1000
Plasma concentration of ONO-2952
(ng/mL)
10010
0
4
8
12
30m
g
60m
g
100m
g
T
im
e (D
ay)
16
20
Figu
re
6
.
T
ro
u
gh
p
la
sm
a
co
n
cen
tratio
n
s
o
f
O
N
O
-2
9
5
2
(m
ean
[S
D
])
fo
llo
w
in
g
m
u
ltip
le
o
ral
ad
m
in
istratio
n
to
h
ealth
y
su
b
jects
in
th
e
m
u
ltip
le
ascen
d
in
g
d
o
se
stu
d
y
(P
h
arm
aco
kin
etic
E
valu
-
ab
le
S
et).
1800
Individual
M
ean
1600
1400
1200
1000
800
600
400
2000
0
20
40
60
D
ose (m
g)
Cmax (ng/mL)
80
100
30000
Individual
M
ean
25000
20000
15000
10000
50000
0
20
40
60
D
ose (m
g)
AUC24h (ng.h/mL)
80
100
Figu
re
7
.
R
elatio
n
sh
ip
b
etw
een
(A
)
p
lasm
a
C
m
a
x
o
r
(B
)
A
U
C
2
4
an
d
d
o
se
o
n
D
ay
2
1
(o
p
en
circles¼
in
d
ivid
u
al
d
ata;
clo
sed
circles¼
arith
m
etic
m
ean
s
[S
D
s]).
C
lin
ical
T
h
erap
eu
tics
2
0
8
2
V
o
lu
m
e
3
7
N
u
m
b
er
9
F. Suto et al.CONCLUSIONS
The novel TSPO antagonist ONO-2952 was safe and
well tolerated in healthy human volunteers following
single doses up to 400 mg or multiple doses up to 100
mg. These results support the progression to addi-
tional clinical trials to evaluate the efﬁcacy and safety
of ONO-2952.
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